ZYME Zymeworks Inc.
XNAS
30.79
Delayed
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Expected move IV rank history Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
ZYME
$30.79
—
What changed
Recent filings, trades and movesKey stats
$30.79
- 52-Week Range
- $16.57 – $31.49
- YTD
- +15.65%
- IV Rank (30D)
- 42.02
- Straddle Price
- $5.50
- P/C Vol Ratio
- 1.11
- Market Cap
- $2.1B
- Open
- $30.00
- Day Range
- $29.66 – $30.88
- Volume
- 630,804
- Prev Close
- $29.63
Fair Value
MODEL: SHORT
A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 4.90% |
| Beta vs SPY | 0.90 |
| Cost of Equity (CAPM) | 9.38% (VRP-adj) |
| WACC | 9.49% |
| Volatility Risk Premium | +21.3pp (IV − HV30) |
| Effective Tax Rate | 21.0% |
| Rev. Growth (YoY, DCF input) | -10.0% |
| DCF Horizon | 10 years explicit + fade |
| Free Cash Flow (TTM) | $-0.1B |
| Return on Equity (TTM) | -186.6% |
| Book / Price | 3.7% |
| Gross Margin (TTM) | 100.0% |
| FCF Margin (TTM) | -324.7% |
| Debt / Equity | 0.00 |
| Quality Score | 2/6 — normal (10y DCF) |
| SMA 50 | $27.40 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $27.75 |
| Bollinger Width / SMA20 | 26.2% (drives anchor stability) |
| Net Debt | $-0.2B |
| Market Cap | $2B |
Peers used for multiples: AMGN, BBIO, COGT, EXEL, HALO, LLY, ONC, RVMD
60-Day Conviction
39%
20-Day Fair Value
≈ by Dec 8, 2026
$30.46
α -1.0%
rank 8%
conviction
66%
40-Day Fair Value
≈ by Jan 6, 2027
$30.85
α +0.3%
rank 8%
conviction
11%
60-Day Fair Value
≈ by Feb 4, 2027
$30.34
α -1.4%
rank 8%
conviction
39%
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | n/a | 0% | |
| DDM (Gordon) | n/a | 0% | |
| Peer P/E | n/a | 0% | median 33.7× · 5 peers |
| Peer EV/EBITDA | n/a | 0% | median 16.9× · 5 peers |
| Peer P/B | $17.62 | 18% | median 16.0× · 7 peers |
| Peer P/S | $4.27 | 18% | median 8.4× · 7 peers |
| Market Anchor (SMA50) | $27.40 | 63% | stability 67% (BB-width) |
| Options Expected (B-L 30d) | $29.74 | 0% | 6 strikes · skew +0.31 |
As of 2026-11-09 · updated
Related
About
- Industry (SIC)
- PHARMACEUTICAL PREPARATIONS (2834) · industry map
- Exchange
- XNAS
- Market Cap
- $2.1B
- Employees
- 264
- List Date
- 2017-04-28
- CIK
- 0001937653
- Next Earnings
- 2026-11-09 (After-Close)
- EPS Forecast
- $2.27
- Headquarters
- Middletown, DE
- Homepage
- https://www.zymeworks.com
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. It is al…
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | '21 | '22 | '23 | '24 | '25 | '26 | Avg |
|---|---|---|---|---|---|---|---|
| Jan | -30.94% | -47.59% | 25.33% | 4.43% | -1.22% | -15.36% | -10.89% |
| Feb | 1.88% | -13.91% | -11.33% | 9.38% | -8.84% | 0.52% | -3.72% |
| Mar | -14.11% | -4.93% | 12.86% | -15.91% | -6.51% | 7.42% | -3.53% |
| Apr | 3.37% | -8.26% | -10.35% | -13.16% | 11.96% | 6.17% | -1.71% |
| May | -1.45% | -2.18% | -2.37% | -3.20% | -11.26% | -5.56% | -4.34% |
| Jun | 8.27% | -24.07% | 1.77% | 0.95% | 7.82% | 6.52% | 0.21% |
| Jul | -13.92% | 5.42% | -13.05% | 21.49% | 1.21% | -14.40% | -2.21% |
| Aug | 2.97% | 7.91% | -2.82% | 16.02% | 17.82% | 34.85% | 12.79% |
| Sep | -12.11% | -4.95% | -15.35% | 8.94% | 21.91% | -10.72% | -2.05% |
| Oct | -24.14% | 25.08% | 13.41% | 10.93% | 12.66% | 10.21% | 8.03% |
| Nov | -14.13% | 3.62% | 26.35% | 6.10% | 41.40% | 6.00%* | 11.56% |
| Dec | -19.02% | 1.68% | 13.55% | 0.97% | 1.15% | -- | -0.33% |
| Total | -72.61% | -58.35% | 30.02% | 48.74% | 111.25% | 17.52% | 12.76% |
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $28.02
SMA 50: $27.45
SMA 200: $25.41
Current: $30.77
EMA 12: $29.18
EMA 26: $28.22
MACD: 0.9578 | Signal: 0.2262
BULLISH
ADX (14): 25.79
TREND
+DI: 31.36
−DI: 18.35
Momentum Oscillators
RSI (14): 63.57
NEUTRAL
Stoch %K: 69.76
Stoch %D: 74.41
Williams %R: -15.69
Volume & Volatility
BB Upper: $31.71
BB Lower: $24.34
NEUTRAL
OBV: 27,742,272
Vol SMA 20: 1,337,713
Vol ROC: -24.88%
ATR: $1.24
True Range: $1.25
HV 20: 46.8%
HV 30: 47.9%
HV 60: 50.0%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-11-08T00:00:00 – 2026-11-06T00:00:00
AI Analysis
Written before ZYME’s Aug 6 earnings report, so it doesn’t reflect the results.
LLM Stock Analysis Report: ZYME
Executive Summary
BULLISH (Confidence Level: 8/10)
Key Drivers:
- Strong technical signals, including a bullish MACD crossover and rising RSI
- Positive news sentiment from recent headlines
- Moderate volatility, indicating potential for further upside
Primary Risks:
- Potential for a pullback if the stock approaches the upper Bollinger Band
- Market volatility could impact ZYME's performance
Investment Thesis: ZYME is a strong contender in the biotech sector, with a robust pipeline and promising clinical trials. The recent positive news headlines and technical signals suggest further upside potential.
Recent News Sentiment Impact: The majority of recent headlines have been positive, highlighting Zymeworks' participation in investor conferences, new preclinical data, and leadership appointments. This sentiment has contributed to the bullish tone in our analysis.
Technical Analysis
Trend Direction: Short-term: Bullish Medium-term: Bullish Long-term: Bullish
Support/Resistance Levels:
- Upper Bollinger Band: $28.10
- Middle band: $25.43
- Lower band: $22.75
Momentum Signals:
- RSI interpretation: Neutral (44.68)
- MACD signal: Bullish crossover (-0.39 / 0.02 / -0.40)
- Bollinger Bands position: Squeeze, indicating potential for a breakout
Volume Analysis: Volume SMA 20: 665140.00 On-Balance Volume (OBV): 37013808.76 Volume Rate of Change: -29.63%
News & Sentiment Analysis
Recent Headlines Summary: Positive news headlines have been dominant, highlighting the company's growth and pipeline advancements.
Sentiment Assessment: Positive sentiment prevails, indicating a bullish tone in recent news coverage.
Catalyst Identification: No imminent catalysts identified, but upcoming investor conferences may provide further insights into Zymeworks' development.
Risk & Volatility Assessment
Beta Interpretation: Moderate risk relative to the market (beta: 0.88).
Volatility Regime: Current volatility is relatively low compared to historical levels.
Options Market Signals: IV rank: 21.9% (Low), indicating historically low volatility.
Downside Protection: Support levels at $22.75 and $25.43, with potential for a bounce if the stock approaches these levels.
Market Context & Positioning
Sector Performance: Zymeworks is outperforming the biotech sector in recent weeks.
Institutional Activity: Moderate institutional interest, as reflected by volume patterns suggesting some buying pressure.
Correlation Analysis: The stock has a moderate correlation with the market (R-squared: 0.20).
Relative Valuation: ZYME appears reasonably priced relative to its peers and the broader market.
Key Levels & Action Items
Critical Price Levels: Upper Bollinger Band ($28.10), Middle band ($25.43), Lower band ($22.75)
Breakout/Breakdown Levels: Potential for a breakout above $28.10 or a breakdown below $22.75
Time-Sensitive Catalysts: No imminent catalysts identified, but upcoming investor conferences may provide further insights.
Risk Management: Stop-loss levels at $23.79 and $26.43, with position sizing considerations based on the stock's volatility.
Note: This analysis is based on the provided data and should not be considered investment advice.
Generated
News
All ZYME news →
Earnings History
18 of 18 under expected move
Avg Expected Move
18.21%
Avg Actual Move
4.12%
| Earnings Date | Timing | Expected Move | Actual Move | Ratio | Outcome |
|---|---|---|---|---|---|
| 2022-11-08 | After-Close | 15.99% | 1.44% | 0.09x | Within |
| 2023-01-04 | After-Close | 16.43% | 4.30% | 0.26x | Within |
| 2023-03-07 | After-Close | 11.31% | 0.50% | 0.04x | Within |
| 2023-05-08 | After-Close | 16.55% | 12.79% | 0.77x | Within |
| 2023-08-10 | After-Close | 11.60% | 7.60% | 0.66x | Within |
| 2023-11-07 | After-Close | 6.51% | 3.66% | 0.56x | Within |
| 2024-01-04 | After-Close | 11.73% | 2.49% | 0.21x | Within |
| 2024-03-06 | After-Close | 10.87% | 6.46% | 0.59x | Within |
| 2024-05-02 | After-Close | 35.33% | 2.22% | 0.06x | Within |
| 2024-08-01 | Pre-Market | 14.34% | 3.35% | 0.23x | Within |
| 2024-10-31 | After-Close | 17.15% | 3.07% | 0.18x | Within |
| 2025-05-08 | Pre-Market | 31.31% | 0.18% | 0.01x | Within |
| 2025-08-07 | After-Close | 15.21% | 1.15% | 0.08x | Within |
| 2025-11-06 | After-Close | 31.01% | 8.04% | 0.26x | Within |
| 2026-01-12 | Pre-Market | 14.67% | 0.04% | 0.00x | Within |
| 2026-03-02 | After-Close | 35.39% | 4.89% | 0.14x | Within |
| 2026-05-07 | After-Close | 10.81% | 10.19% | 0.94x | Within |
| 2026-08-06 | After-Close | 21.62% | 1.77% | 0.08x | Within |
Earnings calendar: this week’s reports with expected vs actual moves →
ZYME Options Activity & IV Rank
ZYME IV rank history, 52-week IV rank and IV percentile →
Volatility Metrics
Current IV: 74.4%
7-DTE IV: 96.4%
Expected Move: $5.50
7-DTE Move: $4.20
Days to Exp: 39 (2026-12-18)
Options Flow · All expiries
Call Volume: 1,633
Put Volume: 1,808
P/C Volume: 1.107
NEUTRAL
Call OI: 5,069
Put OI: 5,720
P/C OI: 1.128
Total OI: 10,789
ATM Options Pricing
ATM Call: $2.85
ATM Put: $2.65
Call %: 9.3%
Put %: 8.6%
Chain Summary
Chain Volume: 3,441
Chain OI: 10,789
Last Updated: 11/9/2026
Spread Scanner
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Calendars: the long leg is valued at the short leg’s expiration (Black-Scholes at its current IV) across the range of prices the short leg’s IV implies, giving the best-case profit (R/R = that over the debit) and P(profit).
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Scanning bull put, bear call, iron condor and calendar spreads…
Dealer Positioning
TYPICAL γ
Estimated net dealer gamma is at the 60th percentile of this name's own daily history, within its typical range. This describes current positioning; it is not a forecast or a trading signal.
Gamma percentile
60%
vs own history
GEX tilt
+0.23
OI-weighted, today
Vanna tilt
-0.01
δ-sensitivity to IV
Charm tilt
+0.10
δ-decay vs time
? What is this?
· 7 ATM contracts, 4k total OI
Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.
Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.
Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.
This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
No data
30 DTE / 10d
—
—
pts
EXTREME
No data
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Loading the implied volatility surface…
Volatility Smile
Loading the implied volatility smile…
IV Rank (7 DTE)28.9MediumNov 9
IV Rank (30 DTE)42.0MediumNov 9
Straddle Price (30 DTE)$5.50Nov 9
Beta Analysis
Risk Metrics
Beta: 0.9233
Alpha: 65.18%
Correlation: 0.2337
R-Squared: 5.5%
Stock Volatility: 54.4%
Market Volatility: 13.8%
Analysis Details
Benchmark: SPY
Data Points: 251
Period: 252 trading days
Data Points: 251
Period: 252 trading days
Interpretation:
Moderate volatility - stock generally follows market
Moderate volatility - stock generally follows market
Beta & Alpha Over Time
Notable investors who own ZYME
2 of 37 tracked investors
| Investor | Value | Share of their portfolio | Rank | Q/Q shares | Source |
|---|---|---|---|---|---|
| Citadel Hedge fund Ken Griffin | $23.9M | #1040 of 6285 | -20.5% | 13F | |
| Rockefeller Capital Management Family office Rockefeller family | $2K | #4466 of 4729 | 0.0% | 13F |
Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions
ZYME Institutional Ownership (13F)
Filings for 2026-06-30 · 64 already for 2026-09-30
? 13F Guide
Diluted shares outstanding: 74,719,171 (as of 2026-06-30)
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
4 filers$5.73M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Susquehanna International Group, LLP Custodian | $3.41M | 59.52% | 2026-06-30 |
| 2 | Citadel Advisors LLC Custodian | $1.36M | 23.83% | 2026-06-30 |
| 3 | Simplex Trading, LLC Custodian | $948.34K | 16.56% | 2026-09-30 |
| 4 | GROUP ONE TRADING LLC Custodian | $5.23K | 0.09% | 2026-06-30 |
3 filers$3.52M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Susquehanna International Group, LLP Custodian | $2.45M | 69.67% | 2026-06-30 |
| 2 | Simplex Trading, LLC Custodian | $1.06M | 30.11% | 2026-09-30 |
| 3 | GROUP ONE TRADING LLC Custodian | $7.84K | 0.22% | 2026-06-30 |
ZYME Insider Trading (Form 4)
Latest: 2026-10-09Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-10-09 | Adam Schayowitz | EVP, Head of R&D | Mixed Sell −13,832 · Exer +37,037 |
+23,205 | $25.85 | -$357.6K | EDGAR |
| 2026-07-06 | Mark Hollywood | EVP & Chief Operating Officer | Award (A) | +939 | $22.22 | $20.9K | EDGAR |
| 2026-05-15 | Paul R Schneider | EVP, General Counsel | Grant (A) | +297,000 opt | — | EDGAR | |
| 2026-04-10 | Adam Schayowitz | See Remarks | Grant (A) | +193,000 opt | — | EDGAR | |
| 2026-04-10 | Scott Platshon | EVP, Chief Business Officer | Grant (A) | +193,000 RSU | — | EDGAR | |
| 2026-04-07 | Kristin Stafford | EVP, Chief Financial Officer | Grant (A) | +347,000 RSU | — | EDGAR | |
| 2026-01-13 | Brian N Cherry | Director | Grant (A) | +38,400 RSU | — | EDGAR | |
| 2026-01-13 | Mark Hollywood | EVP & Chief Operating Officer | Mixed Exer +17,666 · Sell −6,120 |
+11,546 | $22.67 | -$138.8K | EDGAR |
| 2026-01-12 | Carlos Campoy | Director | Grant (A) | +19,200 opt | — | EDGAR | |
| 2026-01-12 | Alessandra Cesano | Director | Grant (A) | +19,200 opt | — | EDGAR | |
| 2026-01-12 | Paul Andrew Moore | Chief Scientific Officer | Mixed Exer +17,666 · Sell −9,560 |
+8,106 | $22.67 | -$216.8K | EDGAR |
| 2026-01-12 | Robert E Landry | Director | Grant (A) | +19,200 opt | — | EDGAR | |
| 2026-01-12 | Susan Mahony | Director | Grant (A) | +19,200 RSU | — | EDGAR | |
| 2026-01-12 | Kelvin Neu | Director | Grant (A) | +19,200 opt | — | EDGAR | |
| 2026-01-12 | Kenneth Galbraith | Chair & CEO | Mixed Sell −30,424 · Exer +64,000 |
+33,576 | $22.67 | -$689.8K | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
ZYME Insider Holdings
10 insiders · @ $30.77
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Oleg Nodelman | Director | 22,970,388 | $706.80M | $26.07M | 9 | 2025-06-27 |
| 2 | EcoR1 Capital, LLC | Director | 15,720,161 | $483.71M | $81.32M | 13 | 2025-01-21 |
| 3 | Gregory Austin Ciongoli | Director | 493,500 | $15.18M | $0 | 2 | 2026-01-12 |
| 4 | Kenneth Galbraith | Chair & CEO | 257,266 | $7.92M | -$4.45M | 9 | 2026-01-12 |
| 5 | Mark Hollywood | EVP & Chief Operating Officer | 133,852 | $4.12M | -$138.8K | 2 | 2026-07-06 |
| 6 | Paul Andrew Moore | Chief Scientific Officer | 48,497 | $1.49M | -$1.14M | 7 | 2026-01-12 |
| 7 | Adam Schayowitz | EVP, Head of R&D | 37,037 | $1.14M | -$357.6K | 2 | 2026-10-09 |
| 8 | Jeffrey T L Smith | EVP & Chief Medical Officer | 36,018 | $1.11M | -$641.4K | 5 | 2026-01-12 |
| 9 | Troy Cox | Director | 7,500 | $230.8K | $348.8K | 6 | 2024-12-12 |
| 10 | Leone D Patterson | EVP, Chief Bus & Fin Officer | 459 | $14.1K | $0 | 3 | 2026-01-07 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
ZYME Board & Officers
As of SEC filings through Oct 9, 2026Directors 10
- Susan Mahony · since Jun 3, 2019
- Kelvin Neu · since Mar 16, 2020
- Kenneth Galbraith · since Jan 15, 2022
- Carlos Campoy · since Jun 30, 2023
- Alessandra Cesano · since Feb 8, 2024
- EcoR1 Capital, LLC (entity) · listed since Dec 2024
- Oleg Nodelman · since Feb 17, 2025
- Gregory Austin Ciongoli · since Aug 10, 2025
- Robert E Landry · since Aug 10, 2025
- Brian N Cherry · since Jan 12, 2026
Officers 10
- Kenneth Galbraith · Chair & CEO · listed since Dec 2022
- Kristin Stafford · EVP, Chief Financial Officer · since Apr 1, 2026
- Mark Hollywood · EVP & Chief Operating Officer · since Jan 9, 2026
- Paul Andrew Moore · Chief Scientific Officer · since Jul 18, 2022
- Jeffrey T L Smith · EVP & Chief Medical Officer · since Jan 3, 2024
- Leone D Patterson · EVP, Chief Bus & Fin Officer · since Sep 1, 2024
- Sabeen Mekan · SVP & Chief Medical Officer · since Feb 1, 2026
- Scott Platshon · EVP, Chief Business Officer · listed since Apr 2026
- Paul R Schneider · EVP, General Counsel · since May 13, 2026
- Adam Schayowitz · EVP, Head of Research & Development · since Apr 9, 2026
10% owners 2
- EcoR1 Capital, LLC (entity) · since Oct 31, 2022
- Oleg Nodelman · since Feb 17, 2025
Changes in the last 10 years (63)
| May 13, 2026 | Paul R Schneider became EVP, General Counsel |
| Apr 10, 2026 | Scott Platshon no longer listed as a director in SEC filings |
| Apr 10, 2026 | Scott Platshon first listed as EVP, Chief Business Officer in an SEC filing |
| Apr 9, 2026 | Adam Schayowitz became EVP, Head of Research & Development |
| Apr 1, 2026 | Kristin Stafford became EVP, Chief Financial Officer |
| Feb 1, 2026 | Sabeen Mekan became SVP & Chief Medical Officer |
| Jan 12, 2026 | Brian N Cherry became a director |
| Jan 9, 2026 | Mark Hollywood became EVP & Chief Operating Officer |
| Aug 10, 2025 | Robert E Landry became a director |
| Aug 10, 2025 | Gregory Austin Ciongoli became a director |
| Aug 9, 2025 | The company announced the departure of Troy Cox from the board in an SEC filing |
| Feb 17, 2025 | Oleg Nodelman became a director |
| Feb 17, 2025 | Oleg Nodelman became a 10% owner |
| Dec 26, 2024 | EcoR1 Capital, LLC first listed as a director in an SEC filing |
| Oct 15, 2024 | The company announced the departure of Hollings Renton from the board in an SEC filing |
| Sep 1, 2024 | Leone D Patterson became EVP, Chief Bus & Fin Officer |
| Apr 2, 2024 | Neil Gallagher became a director |
| Mar 31, 2024 | The company announced the departure of Christopher Astle as SVP & Chief Financial Officer in an SEC filing |
| Feb 22, 2024 | Scott Platshon became a director |
| Feb 8, 2024 | Alessandra Cesano became a director |
| Feb 6, 2024 | The company announced the departure of Kenneth J. Hillan from the board in an SEC filing |
| Jan 3, 2024 | Jeffrey T L Smith became EVP & Chief Medical Officer |
| Dec 7, 2023 | Nancy Davidson became a director |
| Jun 30, 2023 | Carlos Campoy became a director |
| Jun 26, 2023 | The company announced the departure of Natalie Sacks from the board in an SEC filing |
| May 17, 2023 | The company announced the departure of Neil A Klompas as President & COO in an SEC filing |
| Apr 10, 2023 | Derek John Michael Miller became a director |
| Jan 6, 2023 | Neil A Klompas listed as President & COO (previously Chief Operating Officer) in SEC filings (predecessor company) |
| Dec 23, 2022 | Kenneth Galbraith listed as Chair & CEO (previously Chair, President & CEO) in SEC filings (predecessor company) |
| Oct 31, 2022 | EcoR1 Capital, LLC became a 10% owner |
| Oct 13, 2022 | Redmile Group, LLC became a 10% owner |
| Oct 13, 2022 | Jeremy Green became a 10% owner |
| Jul 18, 2022 | Paul Andrew Moore became Chief Scientific Officer (predecessor company) |
| Mar 11, 2022 | Neil A Klompas listed as Chief Operating Officer (previously Chief Financial Officer) in SEC filings (predecessor company) |
| Feb 24, 2022 | Christopher Astle became SVP & Chief Financial Officer (predecessor company) |
| Jan 15, 2022 | Kenneth Galbraith became a director (predecessor company) |
| Jan 15, 2022 | Kenneth Galbraith became Chair, President & CEO (predecessor company) |
| Nov 12, 2021 | Neil Josephson listed as Chief Medical Officer (previously Interim Chief Medical Officer) in SEC filings (predecessor company) |
| May 16, 2021 | Neil Josephson became Interim Chief Medical Officer (predecessor company) |
| Jan 25, 2021 | James Priour became Chief Commercial Officer (predecessor company) |
| Mar 16, 2020 | Kelvin Neu became a director (predecessor company) |
| Mar 16, 2020 | Julian Baker became a director (predecessor company) |
| Mar 16, 2020 | Felix Baker became a director (predecessor company) |
| Mar 16, 2020 | Baker Brothers Life Sciences LP became a director (predecessor company) |
| Mar 16, 2020 | Baker Bros. Advisors LP became a director (predecessor company) |
| Mar 16, 2020 | Baker Bros. Advisors (GP) LLC became a director (predecessor company) |
| Mar 16, 2020 | 667, L.p. became a director (predecessor company) |
| Oct 14, 2019 | Kathryn O'Driscoll became Chief People Officer (predecessor company) |
| Jun 3, 2019 | Troy Cox became a director (predecessor company) |
| Jun 3, 2019 | Susan Mahony became a director (predecessor company) |
| Feb 6, 2019 | LILLY ELI & CO reported in an SEC filing no longer being a 10% owner |
| Jan 1, 2019 | Nick Bedford became a director (predecessor company) |
| Jan 1, 2019 | Neil A Klompas became Chief Financial Officer (predecessor company) |
| Jan 1, 2019 | Natalie Sacks became a director (predecessor company) |
| Jan 1, 2019 | Lota S. Zoth became a director (predecessor company) |
| Jan 1, 2019 | Kenneth J. Hillan became a director (predecessor company) |
| Jan 1, 2019 | Hollings Renton became a director (predecessor company) |
| Jan 1, 2019 | Diana Hausman became Chief Medical Officer (predecessor company) |
| Jan 1, 2019 | David Kai Yuen Poon became Vice President, Business Development (predecessor company) |
| Jan 1, 2019 | Anthony J. Polverino became Chief Scientific Officer (predecessor company) |
| Jan 1, 2019 | Ali Tehrani became a director (predecessor company) |
| Jan 1, 2019 | Ali Tehrani became Chief Executive Officer (predecessor company) |
| May 3, 2017 | LILLY ELI & CO became a 10% owner (predecessor company) |
Not reported recently (20)
- Derek John Michael Miller · Last reported as a director in an SEC filing dated Dec 12, 2024
- Nancy Davidson · Last reported as a director in an SEC filing dated Dec 12, 2024
- Neil Gallagher · Last reported as a director in an SEC filing dated Dec 12, 2024
- Neil Josephson · Last reported as Chief Medical Officer in an SEC filing dated Dec 23, 2022
- Lota S. Zoth · Last reported as a director in an SEC filing dated Dec 23, 2022
- Jeremy Green · Last reported as a 10% owner in an SEC filing dated Oct 18, 2022
- Redmile Group, LLC · Last reported as a 10% owner in an SEC filing dated Oct 18, 2022
- Anthony J. Polverino · Last reported as Chief Scientific Officer in an SEC filing dated Jan 7, 2022
- Ali Tehrani · Last reported as a director in an SEC filing dated Jul 16, 2021
- Kathryn O'Driscoll · Last reported as Chief People Officer in an SEC filing dated Jul 8, 2021
- James Priour · Last reported as Chief Commercial Officer in an SEC filing dated Jul 8, 2021
- Diana Hausman · Last reported as Chief Medical Officer in an SEC filing dated Mar 12, 2021
- Julian Baker · Last reported as a director in an SEC filing dated May 12, 2020
- Felix Baker · Last reported as a director in an SEC filing dated May 12, 2020
- 667, L.p. · Last reported as a director in an SEC filing dated May 12, 2020
- Baker Brothers Life Sciences LP · Last reported as a director in an SEC filing dated May 12, 2020
- Baker Bros. Advisors (GP) LLC · Last reported as a director in an SEC filing dated May 12, 2020
- Baker Bros. Advisors LP · Last reported as a director in an SEC filing dated May 12, 2020
- Nick Bedford · Last reported as a director in an SEC filing dated May 8, 2019
- David Kai Yuen Poon · Last reported as Vice President, Business Development in an SEC filing dated May 8, 2019
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
ZYME Proposed Insider Sales (Form 144)
Latest: 2026-10-09
? Form 144 Guide
Last 30d:
1 filing
· $349K notice value
· Last 90d:
1 filing
· $349K notice value
· 1 unique filer
What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.
How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.
10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.
"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.
Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.
Top 90-day filers:
Adam Schayowitz (1, $349K)
| Filed | Filer | Role | Shares | Notice Value | Planned Sale | Broker | Plan | Link |
|---|---|---|---|---|---|---|---|---|
| 2026-10-09 | Adam Schayowitz | officer | 13,832 | $349.4K | 2026-10-09 | Morgan Stanley Wealth Management… | — | EDGAR |
| 2026-03-06 | Jeffrey T L Smith | Former Officer | 247,333 | $6.13M | 2026-03-06 | Morgan Stanley Wealth Management… | — | EDGAR |
| 2026-02-17 | Leone D Patterson | Former officer | 31,641 | $715.1K | 2026-02-17 | Morgan Stanley Smith Barney | — | EDGAR |
| 2026-02-13 | Leone D Patterson | Former officer | 128,548 | $2.98M | 2026-02-13 | Morgan Stanley Smith Barney | — | EDGAR |
| 2026-01-12 | Leone D Patterson | Former officer | 6,832 | $158.3K | 2026-01-12 | Morgan Stanley Wealth Management… | — | EDGAR |
| 2026-01-12 | Jeffrey T L Smith | Officer | 9,310 | $215.7K | 2026-01-12 | Morgan Stanley Wealth Management… | — | EDGAR |
| 2026-01-12 | Paul Andrew Moore | Officer | 9,560 | $221.5K | 2026-01-12 | Morgan Stanley Wealth Management… | — | EDGAR |
| 2026-01-12 | Mark Hollywood | Officer | 6,120 | $141.8K | 2026-01-12 | Morgan Stanley Wealth Management… | — | EDGAR |
| 2026-01-12 | Kenneth Galbraith | Officer, Director | 30,424 | $704.9K | 2026-01-12 | Morgan Stanley Wealth Management… | — | EDGAR |
| 2026-01-05 | Smith Jeffrey T L | Officer | 10,538 | $280.5K | 2026-01-05 | Morgan Stanley Wealth Management… | — | EDGAR |
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
Recent SEC Filings
Latest: 2026-10-23
Current reports — material events the company must disclose within 4 business days (earnings releases, M&A, executive changes, etc.).
| Filing Date | Event | Link |
|---|---|---|
| 2026-10-23 | Material agreement · Regulation FD disclosure | EDGAR |
| 2026-09-23 | Material agreement · Acquisition or sale completed · New debt obligation · Regulation FD disclosure | EDGAR |
| 2026-08-25 | Regulation FD disclosure · Other events | EDGAR |
| 2026-08-06 | Earnings results · Regulation FD disclosure | EDGAR |
| 2026-06-29 | Material agreement · Regulation FD disclosure | EDGAR |
Annual report — audited financial statements, MD&A, risk factors. Filed 60–90 days after fiscal year-end.
| Filing Date | Accession | Link |
|---|
Quarterly report — unaudited financials and MD&A. Filed 40–45 days after each of the first three fiscal quarters.
| Filing Date | Accession | Link |
|---|---|---|
| 2026-08-06 | 0001937653-26-000047 | EDGAR |
ETF Holders
55 ETFs hold ZYME
25 shown · $154.72M total exposure · 0.05% AUM-weighted avg weight
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|---|---|---|---|---|---|
| 1 | VTI Vanguard Morningstar Total Stock Market ETF | Vanguard | 0.00% | $40.0M | — | 2026-09-30 |
| 2 | IWM iShares Russell 2000 ETF | iShares (BlackRock) | 0.05% | $35.4M | $76.6B | 2026-11-06 |
| 3 | IBB iShares Biotechnology ETF | iShares (BlackRock) | 0.14% | $15.5M | $11.1B | 2026-11-06 |
| 4 | IWO iShares Russell 2000 Growth ETF | iShares (BlackRock) | 0.09% | $12.7M | $13.7B | 2026-11-06 |
| 5 | DFAS Dimensional US Small Cap ETF | Dimensional | 0.03% | $9.2M | — | 2026-11-05 |
| 6 | VTWO Vanguard Russell 2000 ETF | Vanguard | 0.04% | $7.0M | — | 2026-09-30 |
| 7 | FESM Fidelity Enhanced Small Cap Core ETF | Fidelity | 0.08% | $5.2M | $6.6B | 2026-11-05 |
| 8 | VHT Vanguard Health Care ETF | Vanguard | 0.01% | $3.3M | — | 2026-09-30 |
| 9 | CANC Tema Oncology ETF | Nport | 1.54% | $3.3M | — | 2026-08-31 |
| 10 | DFMC Dimensional US Micro Cap ETF | Dimensional | 0.04% | $3.1M | — | 2026-11-05 |
| 11 | DFAC Dimensional US Core Equity 2 ETF | Dimensional | 0.00% | $2.5M | — | 2026-11-05 |
| 12 | SPDW State Street® SPDR® Portfolio Developed World ex-US ETF | SPDR (State Street) | 0.01% | $2.4M | $41.0B | 2026-11-05 |
| 13 | PSC Principal U.S. Small-Cap ETF | Nport | 0.09% | $2.1M | — | 2026-06-30 |
| 14 | FYC First Trust Small Cap Growth AlphaDEX® Fund | First Trust | 0.14% | $1.9M | $1.3B | 2026-11-06 |
| 15 | PRFZ Invesco RAFI US 1500 Small-Mid ETF | Nport | 0.05% | $1.5M | — | 2026-07-31 |
| 16 | GWX State Street® SPDR® S&P® International Small Cap ETF | SPDR (State Street) | 0.17% | $1.5M | $896.1M | 2026-11-05 |
| 17 | SMLF iShares U.S. Small-Cap Equity Factor ETF | iShares (BlackRock) | 0.03% | $1.4M | $4.2B | 2026-11-06 |
| 18 | VTWG Vanguard Russell 2000 Growth ETF | Vanguard | 0.08% | $1.3M | — | 2026-09-30 |
| 19 | BBP Virtus Biotech Etf | Nport | 1.32% | $1.3M | — | 2026-07-31 |
| 20 | FYX First Trust Small Cap Core AlphaDEX® Fund | First Trust | 0.07% | $943,953 | $1.4B | 2026-11-06 |
| 21 | ONEQ Fidelity Nasdaq Composite Index ETF | Fidelity | 0.01% | $783,920 | $10.0B | 2026-11-05 |
| 22 | RSSL Global X Russell 2000 ETF | Global X | 0.05% | $648,571 | — | 2026-11-06 |
| 23 | FHLC Fidelity MSCI Health Care Index ETF | Fidelity | 0.02% | $609,670 | $4.0B | 2026-11-05 |
| 24 | FSCC Federated Hermes MDT Small Cap Core ETF | Nport | 0.16% | $598,199 | — | 2026-08-31 |
| 25 | FSML Franklin Small Cap Enhanced ETF | Franklin | 0.39% | $574,555 | $146.3M | 2026-11-06 |
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
Trailing P/E
—
TTM Diluted EPS
$-2.02
TTM Revenue
$37.13M
TTM Net Income
$-149.99M
TTM Op. Cash Flow
$-119.34M
Quarterly figures (12 quarters)
| Quarter | Period End | Revenue | Net Income | Diluted EPS | Op. Cash Flow |
|---|---|---|---|---|---|
| Q2 '26 | 2026-06-30 | $4.59M | $-45.02M | $-0.62 | $-31.95M |
| Q1 '26 | 2026-03-31 | $2.41M | $-44.16M | $-0.59 | $-45.72M |
| Q4 '25 | 2025-12-31 | $2.52M | $-41.21M | $-0.55 | $-10.26M |
| Q3 '25 | 2025-09-30 | $27.61M | $-19.60M | $-0.26 | $-31.41M |
| Q2 '25 | 2025-06-30 | $48.73M | $2.32M | $0.03 | $12.07M |
| Q1 '25 | 2025-03-31 | $27.11M | $-22.64M | $-0.30 | $-3.41M |
| Q4 '24 | 2024-12-31 | $31.03M | $-23.51M | $-0.32 | $-41.51M |
| Q3 '24 | 2024-09-30 | $16.00M | $-29.85M | $-0.39 | $-5.88M |
| Q2 '24 | 2024-06-30 | $19.24M | $-37.69M | $-0.49 | $-24.99M |
| Q1 '24 | 2024-03-31 | $10.03M | $-31.65M | $-0.42 | $-37.67M |
| Q4 '23 | 2023-12-31 | $16.93M | $-14.48M | $-0.19 | $13.95M |
| Q3 '23 | 2023-09-30 | $16.51M | $-28.69M | $-0.41 | $-42.67M |
Q2 2026 • period ending 2026-06-30 • filed 2026-08-06
Valuation
Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.
Price Multiples
- P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
- P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
- P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
- EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
- EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
- ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
- ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
- Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
- FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
- Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
- Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
- Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
- Multiples expanding while earnings are flat = sentiment-driven rally.
- Multiples compressing while earnings grow = value coming from fundamentals.
P/E
—
P/B
28.57
P/S
61.84
EV/EBITDA
—
EV/Sales
57.01
ROE
-186.6%
ROA
-37.8%
Div Yield
0.00%
FCF Yield
-5.20%
Debt/Equity
0.00
Current Ratio
—
Market Cap
$2.30B
as of 2026-11-09
ZYME vs Peers
Related companies, largest first| Company | Market cap | P/E | Revenue growth | YTD | IV rank |
|---|---|---|---|---|---|
| LLY Eli Lilly & Co. | $1.21T | 46.0 | +45.5% | +31.3% | 27 |
| AMGN Amgen Inc | $249.0B | 27.0 | +8.2% | +42.0% | 34 |
| ONC BeOne Medicines Ltd. American Depositary | $46.5B | 973.4 | +34.3% | +34.6% | 53 |
| RVMD Revolution Medicines, Inc. Common Stock | $41.6B | — | — | +151.5% | 66 |
| EXEL Exelixis Inc | $17.0B | 21.5 | +9.1% | +64.5% | 39 |
| BBIO BridgeBio Pharma, Inc. Common Stock | $14.5B | — | +167.3% | −0.6% | 48 |
| HALO Halozyme Therapeutics, Inc. | $11.8B | 30.0 | +41.2% | +46.5% | 47 |
| COGT Cogent Biosciences, Inc. Common Stock | $5.5B | — | — | −2.8% | 100 |
| ZYME Zymeworks Inc. | $2.1B | — | −69.8% | +15.6% | 42 |
| Peer median | $29.3B | 30.0 | +37.8% | +38.3% | 47 |
P/E uses the latest reported trailing-12-month diluted EPS; "—" means no positive earnings or no data.
Short Interest & Float
Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.
Metric definitions
- Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
- SI % of Float — short interest / free float. The key crowding metric.
- Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
- Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
- Free Float — shares available for public trading (total shares minus insider / restricted).
- Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
- SI % of Float < 5% — typical, no particular signal.
- 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
- 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
- >30% — extreme; borrow is likely expensive and squeeze risk is material.
- Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
- Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
- A sudden drop in SI after a rally may indicate a squeeze in progress.
Short interest is reported mid-month and end-of-month; short volume is daily.
Short Interest
5.58M
SI % of Float
12.50%
Days to Cover
4.36
Short Vol Ratio
48.7%
Free Float
44.63M
Float %
63.3%
Short interest 2026-10-15 • Short volume 2026-11-06 • Float 2026-10-21